Yesterday, the European Society of Medical Oncology (ESMO) released the abstracts to the poster and poster discussion sessions. This preview will be quite long by nature of it being the first time we get a look at the topline details behind some of the key sessions and their abstracts for both immunotherapies (especially checkpoint inhibitors) and targeted therapies. This includes posters and their discussion sessions, plus poster late breaking poster titles.
For reference, you can find the ESMO 2014 poster and poster discussion abstracts can be found here.
In addition, there appears to be some pretty cool presentations in the Special Symposia, which are rather like ASCO scientific symposia and contain a lot of useful information and often strategic ideas about where thought leaders see hot topics going in the future. This can be very helpful in learning about possibilities for new clinical trials ahead of time. As we focus on the poster highlights today, do check back tomorrow for a detailed look at the scientific symposia.
Premium subscribers and those interested in signing up for our Conference Coverage service can log-in to access our latest insights from the ESMO 2014 meeting.
One of the interesting new developments at AACR was the return of FGFR inhibitors with more enthusiasm and encouraging data compared to the past. Recall that previous small molecule inhibitors such as brivanib (BMS) and dovitinib (Novartis) didn’t fare particularly well, despite a multitude of clinical trials in different tumour types where FGFR was thought to matter.
This begs several key questions:
- Does the target matter to the tumour?
- Do we have enough therapeutic index to shut down the pathway?
- Is it better to be a specific or a pan-FGFR inhibitor?
- Does having multi-kinase effects offer off-target adverse events to the detriment of efficacy?
- Do we need an antibody or an ADC rather than a small molecule to improve potency?
And many other questions that cannot be addressed or answered on the basis of two chemical entities.
Interestingly, and perhaps even surprisingly, new data emerged in San Diego that might help us answer some of these questions.
In this review, a number of anti-FGFR compounds are mentioned including brivanib (BMS), dovitinib (Novartis), lenvatinib (Eisai), ponatinib (Ariad), BGJ398 (Novartis) and BAY 1179470 (Bayer).
Here, we take a particular focus on promising new FGFR compounds with new data at AACR from Novartis (BGJ398) and Bayer (BAY 1179470, BAY 1163877, FGFR2-ADC).
Subscribers can log-in to read our latest insights or you can purchase access to BSB Premium Content.